摘要
目的:分析曲美他嗪治疗慢性心力衰竭的临床效果及对心功能与超敏C-反应蛋白的影响。方法:选取2015年8月至2017年10月94例慢性心力衰竭患者作为研究对象,按随机数表法分为对照组(n=47)和研究组(n=47)。对照组予以常规治疗,研究组在对照组基础上联合曲美他嗪治疗。比较两组临床效果、左心室短轴缩短率(FS)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、心功能分级以及血清白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C-反应蛋白(hsCRP)水平变化,及心脏不良事件发生情况。结果:治疗后,研究组有效率高于对照组95.74%比80.85%,差异具有统计学意义(P<0.05)。两组FS、LVEF均上升,研究组高于对照组,两组LVEDD以及NYHA分级均下降,研究组下降幅度更明显,比较有统计学差异(P<0.05)。两组血清IL-6、TNF-α以及hs-CRP水平较下降,研究组低于对照组(P<0.05)。两组均有血栓形成、心律失常出现,但研究组发生率低于对照组,组间比较有差异(P<0.05)。结论:曲美他嗪治疗慢性心力衰竭可有效降低血清超敏C-反应蛋白水平,改善其心功能情况,提高临床综合治疗效果。
Objective:To study the clinical effect of trimetazidine in treatment of chronic heart failure and its effect on cardiac function and high sensitivity c-reactive protein.Methods:94 patients with chronic heart failure from August 2015 to October 2017 in our hospital were selected,according to random table method,those patients were divided into control group(n=47)and research group(n=47).control group were treated with routine therapy.research group were treated with trimetazidine based on the control group.Then clinical treatment effect,Left ventricular ejection fraction(LV),left ventricular ejection fraction(LVEF),cardiac function classification,serum interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α),hs-CRP and acute cardiac events between two group was compared.Results:After treatment,the effective rate of research group was significantly higher than the control group 95.74%vs 80.85%,there was statistically significant(P<0.05).the FS and LVEF in two group was up,the research group was higher than the control group,and LVEDD and NYHA in two group were decreased,and the decrease was more obvious in the research group,there was statistically significant(P<0.05).IL-6,TNF-α,hs-CRP in the two groups decreased,and the research group was lower than the control group(P<0.05).There were thrombosis and arrhythmia in both groups,but the rate of the research group was lower than the control group,and there was a difference between the groups(P<0.05).Conclusion:Application of trimetazidine in the treatment of chronic heart failure can effectively reduce serum high-sensitivity C-reactive protein levels,improve their cardiac function,improve the clinical efficacy of comprehensive treatment.
作者
程德均
CHENG Dejun(China Aviation Industry 3201 Hospital,Shaanxi Hanzhong 72300,China)
出处
《河北医学》
CAS
2018年第4期619-622,共4页
Hebei Medicine
基金
陕西省科技计划项目
(编号:2012B1229)
关键词
曲美他嗪
慢性心力衰竭
心功能
超敏C-反应蛋白
Trimetazidine
chronic heart failure
Heart function
Hypersensitive C-reactive protein
